ProKidney (PROK) vs SL Science (SLBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
ProKidney (PROK) has outperformed SL Science (SLBT) over the past year, losing 47.3% versus a loss of 85.4%. SL Science is the larger company by market cap ($846.7 million vs $694.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | SLBT |
|---|---|---|
| Share price | $1.74 | $1.51 |
| Market cap | $694.58M | $846.75M |
| 1-day change | +4.82% | -0.66% |
| YTD return | -22.32% | -85.68% |
| 1-year return | -47.27% | -85.42% |
| 5-year return | -82.37% | — |
| EPS (TTM) | $-0.57 | $-0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.48 | $14.50 |
| 52-week low | $1.30 | $1.42 |
| Distance from 52-week high | -50.00% | -89.59% |
| Analyst consensus | none | — |
| Avg. price target upside | +259.20% | — |
| Average volume | 1.30M | 79.13K |
| Shares outstanding | 208.93M | 560.76M |
| Employees | 231 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PROK has outperformed SLBT by 38.1 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About SL Science
SLBT stock →SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
PROK vs SLBT FAQ
Which is bigger, ProKidney or SL Science?
SL Science (SLBT) is larger, with a market capitalization of $846.75M compared with $694.58M for ProKidney (PROK).
Which stock has performed better over the past year, PROK or SLBT?
PROK returned -47.27% over the past 12 months, compared with -85.42% for SLBT (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and SL Science in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.